Geographic atrophy (GA) is sight threatening. It causes loss of central vision, development of scotomas (blind spots), reduced reading speed and night vision …
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
NEW YORK and LONDON, September 5, 2023(GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced …
[Read more...] about Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
NEW YORK and LONDON, August 18, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
Akari Therapeutics, Plc Announces ADS Ratio Change
NEW YORK and LONDON, August 15, 2023 (GLOBE NEWSWIRE) – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
[Read more...] about Akari Therapeutics, Plc Announces ADS Ratio Change
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
NEW YORK and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
